Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
The acquisition creates the ninth-largest U.S. bank and signals accelerating consolidation within the regional banking sector.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
The all-stock deal marks a significant move in the ongoing consolidation wave among U.S. regional banks, creating a new top-ten lender.
Despite a revenue beat, the semiconductor equipment supplier's net loss and missed earnings per share estimates sent shares tumbling in after-hours trading.
The executive search firm's shares jumped over 19% after agreeing to an all-cash acquisition by an investor group led by Advent International and Corvex.
All-stock transaction marks significant consolidation in the regional banking sector, creating the 9th largest U.S. bank by assets.